Lawreen H Connors

List of Publications by Year
in descending order

95 papers	4,696 citations	101496 36 h-index	102432 66 g-index
96 all docs	96 docs citations	96 times ranked	3643 citing authors

#	Article	IF	Citations
1	Tabulation of human transthyretin (TTR) variants, 2003. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 160-184.	1.4	449
2	Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress. Circulation Research, 2004, 94, 1008-1010.	2.0	358
3	Senile Systemic Amyloidosis Presenting With Heart Failure. Archives of Internal Medicine, 2005, 165, 1425.	4.3	315
4	Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38Î± MAPK pathway. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4188-4193.	3.3	264
5	Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts. Circulation, 2001, 104, 1594-1597.	1.6	233
6	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circulation, 2016, 133, 282-290.	1.6	230
7	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. Molecular and Cellular Proteomics, 2008, 7, 1570-1583.	2.5	134
8	Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival. Arthritis and Rheumatism, 2007, 56, 3858-3868.	6.7	130
9	Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. American Heart Journal, 2009, 158, 607-614.	1.2	129
10	Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood, 2011, 118, 6610-6617.	0.6	127
11	Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H95-H103.	1.5	123
12	Sequence Communication: Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 54-69.	1.4	122
13	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67.	1.4	108
14	Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chainâ€mediated cardiotoxicity. EMBO Molecular Medicine, 2014, 6, 1493-1507.	3.3	106
15	Features of atrial fibrillation in wildâ€type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Failure, 2018, 5, 772-779.	1.4	89
16	The Critical Role of the Constant Region in Thermal Stability and Aggregation of Amyloidogenic Immunoglobulin Light Chain. Biochemistry, 2010, 49, 9848-9857.	1.2	79
17	AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 1-8.	1.4	70
18	Heterogeneity in Primary Structure, Post-Translational Modifications, and Germline Gene Usage of Nine Full-Length Amyloidogenic Î»1 Immunoglobulin Light Chains. Biochemistry, 2007, 46, 14259-14271.	1.2	61

#	Article	IF	Citations
19	Characterization of Transthyretin Variants in Familial Transthyretin Amyloidosis by Mass Spectrometric Peptide Mapping and DNA Sequence Analysis. Analytical Chemistry, 2002, 74, 741-751.	3.2	57
20	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure, 2020, 26, 753-759.	0.7	57
21	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Research in Cardiology, 2013, 108, 378.	2.5	56
22	Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis. Journal of Proteome Research, 2017, 16, 1659-1668.	1.8	56
23	Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circulation: Heart Failure, 2018, 11, e004000.	1.6	55
24	Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis. Circulation: Heart Failure, 2008, 1, 249-257.	1.6	53
25	Cellular Response of Cardiac Fibroblasts to Amyloidogenic Light Chains. American Journal of Pathology, 2005, 166, 197-208.	1.9	51
26	The Modulation of Transthyretin Tetramer Stability by Cysteine 10 Adducts and the Drug Diflunisal. Journal of Biological Chemistry, 2008, 283, 11887-11896.	1.6	51
27	Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and Fibrils. Journal of Biological Chemistry, 2010, 285, 37672-37682.	1.6	49
28	Identification ofS-sulfonation andS-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Science, 2003, 12, 1775-1785.	3.1	48
29	Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. JAMA Cardiology, 2017, 2, 305.	3.0	48
30	Role of Endocytic Inhibitory Drugs on Internalization of Amyloidogenic Light Chains by Cardiac Fibroblasts. American Journal of Pathology, 2006, 169, 1939-1952.	1.9	47
31	Evidence for a Functional Role of the Molecular Chaperone Clusterin in Amyloidotic Cardiomyopathy. American Journal of Pathology, 2011, 178, 61-68.	1.9	46
32	Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal, 2021, 11, 139.	2.8	45
33	Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 210-215.	1.4	44
34	A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1998, 1407, 185-192.	1.8	43
35	Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis. Stem Cell Reports, 2013, 1, 451-463.	2.3	42
36	Association of acquired von Willebrand syndrome with AL amyloidosis. American Journal of Hematology, 2007, 82, 363-367.	2.0	39

#	Article	IF	Citations
37	Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 255-261.	1.4	39
38	Betabellins 15D and 16D, de Novo Designed Î²-Sandwich Proteins That Have Amyloidogenic Properties. Journal of Structural Biology, 2000, 130, 363-370.	1.3	36
39	Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the Seventh Decade of Life. Journal of Molecular Diagnostics, 2014, 16, 68-74.	1.2	35
40	Biophysical analysis of normal transthyretin: Implications for fibril formation in senile systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 75-83.	1.4	31
41	Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Scientific Reports, 2019, 9, 8552.	1.6	31
42	Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6428-E6436.	3.3	26
43	Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. European Journal of Haematology, 2020, 105, 495-501.	1.1	26
44	Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis. Journal of the American Heart Association, 2013, 2, e005868.	1.6	25
45	Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin. Protein Expression and Purification, 2007, 53, 370-377.	0.6	24
46	Thermodynamic Stability of a Îº I Immunoglobulin Light Chain: Relevance to Multiple Myeloma. Biophysical Journal, 2005, 88, 4232-4242.	0.2	21
47	Cooperative Stabilization of Transthyretin by Clusterin and Diflunisal. Biochemistry, 2015, 54, 268-278.	1.2	21
48	Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal, 2020, 10, 118.	2.8	21
49	Transthyretin Aggregate-Specific Antibodies Recognize Cryptic Epitopes on Patient-Derived Amyloid Fibrils. Rejuvenation Research, 2014, 17, 97-104.	0.9	20
50	Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Human Genetics, 2015, 134, 111-121.	1.8	20
51	A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 182-185.	1.4	19
52	A new transthyretin variant (Ser2 sn) associated with familial amyloidosis in a Portuguese patient. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 114-118.	1.4	18
53	Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 134-140.	1.4	18
54	Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant. Kidney International Reports, 2017, 2, 1223-1232.	0.4	17

#	Article	IF	Citations
55	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 103-107.	1.4	16
56	A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 61-66.	1.4	14
57	Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 120-121.	1.4	14
58	A new era of amyloidosis: the trends at a major US referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 192-196.	1.4	14
59	Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. American Journal of Cardiology, 2019, 124, 122-130.	0.7	14
60	Oxidative post-translational modifications of an amyloidogenic immunoglobulin light chain protein. International Journal of Mass Spectrometry, 2017, 416, 71-79.	0.7	13
61	A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 148-155.	1.4	13
62	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 71-78.	1.4	13
63	Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic AmyloidÂDisease. Stem Cell Reports, 2020, 15, 515-528.	2.3	12
64	Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation. Analytical Biochemistry, 2012, 425, 151-156.	1.1	11
65	Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 263-267.	1.4	10
66	A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 65-71.	1.4	9
67	Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 253-255.	1.4	9
68	Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. Biochemistry, 2020, 59, 1800-1803.	1.2	9
69	A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin Î»6 Light Chain Promotes Pathologic Amyloid Formation. Journal of Molecular Biology, 2021, 433, 167310.	2.0	9
70	Dysregulation of miRNAs in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 128-135.	1.4	8
71	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 214-220.	1.4	8
72	Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 184-189.	1.4	8

#	Article	IF	Citations
73	In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 115-122.	1.4	6
74	Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm). Journal of Proteome Research, 2017, 16, 4104-4112.	1.8	5
75	Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses. Biochemistry, 2020, 59, 4367-4378.	1.2	5
76	Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Medicine, 2022, 4, 100427.	1.0	4
77	Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 156-162.	1.4	2
78	A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis. Blood, 2021, 138, 155-155.	0.6	2
79	A novel substitution of proline (P32L) destabilises Î²2-microglobulin inducing hereditary systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, , 1-8.	1.4	2
80	Effect of diflunisal on clusterin levels in ATTRwt amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 49-50.	1.4	1
81	Structural studies of serum clusterin in ATTRwt amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 51-52.	1.4	1
82	Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis. Current Clinical Pathology, 2015, , 343-353.	0.0	1
83	Familial wild-type transthyretin cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 91-92.	1.4	0
84	Analysis of the non-coding rs3764479 mutation in the proximal promoter of the transthyretin gene. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 83-84.	1.4	0
85	Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.. Blood, 2005, 106, 4078-4078.	0.6	0
86	Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity.. Blood, 2005, 106, 3412-3412.	0.6	0
87	Human Amyloidogenic Light Chains Alter Cardiomyocyte Signaling Through Disruption of Heparan Sulfate Proteoglycan (HSPG) Complex. FASEB Journal, 2006, 20, A935.	0.2	0
88	Dysregulation of miRNAs In AL Amyloidosis. Blood, 2010, 116, 4648-4648.	0.6	0
89	Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis and Other Plasma Cell Dyscrasias. , 2012, , 283-290.		0
90	Transthyretin Stabilizers: Preventing Amyloidosis. FASEB Journal, 2012, 26, .	0.2	0

#	Article	IF	Citations
91	The circulating molecular chaperone clusterin interacts with amyloidogenic transthyretin oligomers and modulates amyloid formation. FASEB Journal, 2013, 27, 996.9.	0.2	0
92	Single nucleotide polymorphisms in the 3â€² untranslated and near gene regions of transthyretin may play a role in senile systemic amyloidosis. FASEB Journal, 2013, 27, 874.30.	0.2	0
93	Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio. Blood, 2015, 126, 2956-2956.	0.6	0
94	The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades. Blood, 2018, 132, 5536-5536.	0.6	0
95	Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51.	0.6	0